Gupta, V., Yacoub, A., Fazal, S., Miller, C., Verstovsek, S., Mesa, R., … Talpaz, M. (2020). MPN-183: Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. In Clinical Lymphoma Myeloma and Leukemia (Vol. 20, pp. S331–S332). Elsevier BV. https://doi.org/10.1016/s2152-2650(20)30995-2

Gupta, Vikas, Abdulraheem Yacoub, Salman Fazal, Carole Miller, Srdan Verstovsek, Ruben Mesa, Claire Harrison, et al. “MPN-183: Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib.” In Clinical Lymphoma Myeloma and Leukemia, 20:S331–32. Elsevier BV, 2020. https://doi.org/10.1016/s2152-2650(20)30995-2.

Gupta V, Yacoub A, Fazal S, Miller C, Verstovsek S, Mesa R, et al. MPN-183: Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2020. p. S331–2.

Gupta, Vikas, et al. “MPN-183: Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib.” Clinical Lymphoma Myeloma and Leukemia, vol. 20, Elsevier BV, 2020, pp. S331–32. Crossref, doi:10.1016/s2152-2650(20)30995-2.

Gupta V, Yacoub A, Fazal S, Miller C, Verstovsek S, Mesa R, Harrison C, Barosi G, Kiladjian J-J, Mattison R, Rein L, Reeves B, Oh S, Parameswaran V, Deeg J, Rose S, Chia V, Wang T, Talpaz M. MPN-183: Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2020. p. S331–S332.